{"id":2464,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2000-09-29","marketCap":27.392610549926758,"name":"Aspira Women's Health Inc","phone":"15125190400","outstanding":10.34000015258789,"symbol":"AWH","website":"https://aspirawh.com/","industry":"Health Care"},"price":2.675,"year":2023,"month":12,"day":19,"weekday":"Tuesday","title":"The Potential Impact of Consumer Discretionary Spending on Aspira Women's Health Inc's Stock Performance","date":"2023-12-19","url":"/posts/2023/12/19/AWH","content":[{"section":"Introduction","text":"Aspira Women's Health Inc is a company that focuses on developing and commercializing innovative diagnostic tests for women's health conditions. The company's stock performance can be influenced by various factors, including changes in consumer discretionary spending. Consumer discretionary spending refers to the amount of money consumers choose to spend on non-essential products and services, such as luxury goods, travel, and entertainment."},{"section":"Exposure to Consumer Spending Patterns","text":"Aspira Women's Health Inc's exposure to consumer spending patterns can be analyzed by considering its products and target market. The company offers diagnostic tests for gynecological conditions, such as ovarian and endometrial cancers. These tests are typically recommended by healthcare professionals based on patients' symptoms and risk factors. Therefore, Aspira Women's Health Inc relies on consumers seeking medical advice and receiving appropriate testing for the detection of these conditions."},{"section":"Impact of Changes in Consumer Discretionary Spending","text":"Changes in consumer discretionary spending can affect Aspira Women's Health Inc's stock performance in several ways. Firstly, if consumers reduce their spending on healthcare services, including diagnostic tests, the demand for Aspira Women's Health Inc's products may decrease. This could lead to lower sales and potentially impact the company's revenue and profitability, which could then be reflected in its stock price."},{"section":"On the other hand, an increase in consumer discretionary spending could have a positive impact on Aspira Women's Health Inc's stock performance.","text":"As consumers have more disposable income to spend on healthcare services, they may be more willing to undergo diagnostic tests for early detection and prevention of women's health conditions. This could lead to higher demand for Aspira Women's Health Inc's products and potentially drive up the company's sales, revenue, and stock price."},{"section":"Conclusion","text":"Aspira Women's Health Inc's stock performance is intricately linked to changes in consumer discretionary spending. Decreases in consumer spending on healthcare services could negatively affect the company's sales and profitability, potentially leading to a decline in its stock price. Conversely, an increase in consumer discretionary spending could have a positive impact on the company's stock performance by driving up demand for its diagnostic tests. Investors should closely monitor consumer spending patterns and their potential impact on Aspira Women's Health Inc's financial performance and stock price."}],"tags":["CrossUnder100","Short","Health Care"],"news":[{"category":"company","date":1702558800,"headline":"Aspira Women’s Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024","id":124510806,"image":"https://media.zenfs.com/en/globenewswire.com/23cdaf88e2e9a13bfdb9c92d2e5516fc","symbol":"AWH","publisher":"Yahoo","summary":"Aspira management will be available for meetings in San Francisco (January 8-10, 2024) AUSTIN, Texas, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will be available for partnering and institutional one-on-one meetings in San Francisco, during JP Morgan’s Healthcare Conference Week 2024. Nicole","url":"https://finance.yahoo.com/news/aspira-women-health-participate-corporate-130000690.html"},{"category":"company","date":1702046760,"headline":"New to The Street TV Features Five Corporate Guest Interviews, Episode 537 Airs on the FOX Business Network, Monday, December 11, 2023, at 10:30 PM PT","id":124388115,"image":"https://media.zenfs.com/en/globenewswire.com/e4a09a8ad567c697ca5255b519cf66ba","symbol":"AWH","publisher":"Yahoo","summary":"New to The Street TV Features Five Corporate Guest Interviews, Episode 537 Airs on the FOX Business Network, Monday, December 11, 2023, at 10;30 PM PT Episode 537: 1). Reliance Global Group, Inc. (NASDAQ: RELI) (NASDAQ: RELIW) ($RELI) 2). Aspira Women's Health (NASDAQ: AWH) ($AWH) 3). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 4).The Business of Blockchain, 5).Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) - https://www.newtothestreet.com/ NEW YORK, Dec. 08, 202","url":"https://finance.yahoo.com/news/street-tv-features-five-corporate-144600705.html"},{"category":"company","date":1701958800,"headline":"New to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PT","id":124358734,"image":"https://media.zenfs.com/en/globenewswire.com/6a0ed10ceb079dc697d1bbaa456d19c5","symbol":"AWH","publisher":"Yahoo","summary":"New to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PT Episode 536: 1). - Reliance Global Group, Inc. (NASDAQ: RELI) (NASDAQ: RELIW) ($RELI) 2). Aspira Women's Health (NASDAQ: AWH) ($AWH) 3). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 4). The Business of Blockchain 5).Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) - https://www.ne","url":"https://finance.yahoo.com/news/street-tv-announces-episode-536-142000722.html"},{"category":"company","date":1701940860,"headline":"Aspira Women's Health CEO Nicole Sandford discloses purchase of over 5K shares","id":124360998,"image":"","symbol":"AWH","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3246012183"},{"category":"company","date":1701934680,"headline":"$1.7M Bet On Erasca? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying","id":124360277,"image":"","symbol":"AWH","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3245882415"},{"category":"company","date":1701867600,"headline":"Aspira Women’s Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis","id":124350559,"image":"https://media.zenfs.com/en/globenewswire.com/23cdaf88e2e9a13bfdb9c92d2e5516fc","symbol":"AWH","publisher":"Yahoo","summary":"Data supports EndoCheck™ to be the first blood test for the identification of localized endometriosis, including endometrioma Platform migration to begin on the Company’s EndoMDx™ test for broader endometriosis indications AUSTIN, Texas, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has completed the de","url":"https://finance.yahoo.com/news/aspira-women-health-provides-development-130000832.html"},{"category":"company","date":1701846660,"headline":"Aspira Women's Health provides development update on EndoCheck","id":124334380,"image":"","symbol":"AWH","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3243965107"}]}